Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • EU endorses new...

    EU endorses new measures to protect women from valproate epilepsy drug

    Written by Ruby Khatun Khatun Published On 2018-06-14T09:30:11+05:30  |  Updated On 14 Jun 2018 9:30 AM IST
    EU endorses new measures to protect women from valproate epilepsy drug

    PARIS: French regulator ANSM said epilepsy drug valproate would face new restrictions across the European Union to protect pregnant women or of child-bearing age from exposing their babies to possible malformations and developmental problems.


    “Valproate is forbidden during pregnancy and should no longer be prescribed to girls, teenagers, and women of child-bearing age unless exceptional circumstances,” France’s Agence Nationale de Securite du Medicament said in a statement.


    The statement echoed a decision by the European Commission made public earlier this year by the European Medicines Agency.


    “The new measures include a ban on the use of such medicines for migraine or bipolar disorder during pregnancy and a ban on treating epilepsy during pregnancy unless there is no other effective treatment available,” the EMA said of valproate.


    “Further, the medicines must not be used in any woman or girl able to have children unless the conditions of a new pregnancy prevention program are met.”





    Prescribed globally for epilepsy and bipolar disorders - and in some cases migraines - valproate is included in the World’s Health Organization list of essential medicines.



    But the drug, manufactured by French drugmaker Sanofi and sold under brands such as Depakine, Depakote and Epilim, is also known to have caused birth malfunctions and slow neurological development after being taken during pregnancy.


    Earlier this year, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recommended measures to avoid valproate exposure in pregnancy but did not call for a ban.




    It said that the outer packaging of all valproate medicines must include a visual warning about the risks in pregnancy.


    “The European Commission decision endorsed the PRAC recommendations. Sanofi will follow theses recommendations to revise the product information for epilepsy and bipolar disorder, and will do so across Europe and worldwide” a spokesman for the company said in an emailed statement.





    (Reporting by Matthias Blamont; Editing by Matthew Mpoke Bigg)




    ANSMbipolar disorderendorsesEpilepsyepilepsy drugessential medicinesEUEuropean CommissionEuropean UnionmalformationsMigrainenew measurespregnant womenprotectSanofivalproatewomen
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok